James M Frates - Net Worth and Insider Trading
James M Frates Net Worth
The estimated net worth of James M Frates is at least $7 Million dollars as of 2024-12-12. James M Frates is the SVP, Alks Inc; CFO ALKS of Alkermes PLC and owns about 183,438 shares of Alkermes PLC (ALKS) stock worth over $6 Million. James M Frates is the CFO of Amylyx Pharmaceuticals Inc and owns about 244,536 shares of Amylyx Pharmaceuticals Inc (AMLX) stock worth over $1 Million. James M Frates is also the Director of Sage Therapeutics Inc and owns about 2,845 shares of Sage Therapeutics Inc (SAGE) stock worth over $16,757. Details can be seen in James M Frates's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that James M Frates has not made any transactions after 2024-09-12 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of James M Frates
James M Frates Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, James M Frates owns 3 companies in total, including Sage Therapeutics Inc (SAGE) , Alkermes PLC (ALKS) , and Amylyx Pharmaceuticals Inc (AMLX) .
Click here to see the complete history of James M Frates’s form 4 insider trades.
Insider Ownership Summary of James M Frates
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| SAGE | Sage Therapeutics Inc | 2021-06-16 | director |
| ALKS | Alkermes PLC | 2018-06-12 | SVP & CFO & Alkermes plc |
| AMLX | Amylyx Pharmaceuticals Inc | 2024-09-12 | Chief Financial Officer |
James M Frates Latest Holdings Summary
James M Frates currently owns a total of 3 stocks. Among these stocks, James M Frates owns 183,438 shares of Alkermes PLC (ALKS) as of June 12, 2018, with a value of $6 Million and a weighting of 83.95%. James M Frates owns 244,536 shares of Amylyx Pharmaceuticals Inc (AMLX) as of September 12, 2024, with a value of $1 Million and a weighting of 15.81%. James M Frates also owns 2,845 shares of Sage Therapeutics Inc (SAGE) as of June 16, 2021, with a value of $16,757 and a weighting of 0.25%.
Latest Holdings of James M Frates
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ALKS | Alkermes PLC | 2018-06-12 | 183,438 | 30.94 | 5,675,572 |
| AMLX | Amylyx Pharmaceuticals Inc | 2024-09-12 | 244,536 | 4.37 | 1,068,622 |
| SAGE | Sage Therapeutics Inc | 2021-06-16 | 2,845 | 5.89 | 16,757 |
Holding Weightings of James M Frates
James M Frates Form 4 Trading Tracker
According to the SEC Form 4 filings, James M Frates has made a total of 0 transactions in Alkermes PLC (ALKS) over the past 5 years. The most-recent trade in Alkermes PLC is the sale of 16,842 shares on June 12, 2018, which brought James M Frates around $842,100.
According to the SEC Form 4 filings, James M Frates has made a total of 7 transactions in Amylyx Pharmaceuticals Inc (AMLX) over the past 5 years, including 1 buys and 6 sells. The most-recent trade in Amylyx Pharmaceuticals Inc is the acquisition of 40,000 shares on September 12, 2024, which cost James M Frates around $101,200.
According to the SEC Form 4 filings, James M Frates has made a total of 1 transactions in Sage Therapeutics Inc (SAGE) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Sage Therapeutics Inc is the acquisition of 1,810 shares on June 16, 2021, which cost James M Frates around $99,731.
Insider Trading History of James M Frates
- 1
James M Frates Trading Performance
GuruFocus tracks the stock performance after each of James M Frates's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by James M Frates is 39.26%. GuruFocus also compares James M Frates's trading performance to market benchmark return within the same time period. The performance of stocks bought by James M Frates within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how James M Frates's insider trading performs compared to the benchmark.
Performance of James M Frates
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 14.78 | | | | | |
| Relative Return to S&P 500(%) | 11.6 | | | | | |
James M Frates Ownership Network
Ownership Network List of James M Frates
Ownership Network Relation of James M Frates
James M Frates Owned Company Details
What does Sage Therapeutics Inc do?
Who are the key executives at Sage Therapeutics Inc?
James M Frates is the director of Sage Therapeutics Inc. Other key executives at Sage Therapeutics Inc include director & See Remarks Jeffrey M Jonas , Chief Medical Officer Laura Gault , and Chief Commercial Officer Christopher Benecchi .
Sage Therapeutics Inc (SAGE) Insider Trades Summary
Over the past 18 months, James M Frates made no insider transaction in Sage Therapeutics Inc (SAGE). Other recent insider transactions involving Sage Therapeutics Inc (SAGE) include a net purchase of 2,000 shares made by Elizabeth Barrett ,
In summary, during the past 3 months, insiders sold 0 shares of Sage Therapeutics Inc (SAGE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sage Therapeutics Inc (SAGE) were sold and 2,000 shares were bought by its insiders, resulting in a net purchase of 2,000 shares.
Sage Therapeutics Inc (SAGE)'s detailed insider trading history can be found in Insider Trading Tracker table.
Sage Therapeutics Inc Insider Transactions
James M Frates Mailing Address
Above is the net worth, insider trading, and ownership report for James M Frates. You might contact James M Frates via mailing address: 88 Sidney St, Cambridge Ma 021394136.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
